Welcome and Introduction to Vi3C

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

Opening Session Panel Discussion

Aug

Today In Oncology

Welcome and Introduction to Vi3C

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Amit Sanyal, MD: A Clinician’s Perspective

Opening Session Panel Discussion

Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care

AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

NIH-Funded International Research Yields Patient-Derived Tumor Compendium

Stanford Appoints New Leader to Expand Impact in Early Drug Development